Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Cowen Inc from $95.00 to $100.00.
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Morgan Stanley from $69.00 to $65.00. They now have an "equal weight" rating on the stock.MarketBeat
- 1 Healthcare Stock on Our Watchlist and 2 to Brush Off [Yahoo! Finance]Yahoo! Finance
- Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib [Seeking Alpha]Seeking Alpha
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Truist Financial Co. from $74.00 to $72.00. They now have a "hold" rating on the stock.MarketBeat
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.MarketBeat
INCY
Earnings
- 2/10/25 - Beat
INCY
Sec Filings
- 3/18/25 - Form 4
- 3/14/25 - Form 144
- 3/6/25 - Form 4
- INCY's page on the SEC website